Exxon Mobil Misses Bottom Line Estimates As Production Comes In Shy (XOM)

4-26-12-Exxon Mobil (NYSE:XOM) reported Q1 EPS of $2.00, missing estimates of $2.08. The company has missed estimates 3 out of the last 4 quarters.The company reported Q1 revenues of $124.05 billion, vs. estimates of $119.9 billion.Exxon reported production of 4.55 Mboe per day vs. estimates of 4.67 Mboe per day.Exxon said it repurchased $5 billion worth of shares in the quarter and expects to repurchase $5 billion in the second quarter.Exxon said segment earnings were as follows; E&P $7.8b vs. estimates of $8.58 billion, R&M $1.59 billion vs. estimates of $959 million, chemicals $701 million vs. estimates of $1.05 billion.SmarTrend currently has Exxon Mobil in a Downtrend. Since 2008, SmarTrend subscribers trading Exxon Mobil using our alerts outperformed the stock by 78%. We are monitoring these developments and will alert subscribers to any change in trend.

Repligen Tumbles 45% On Pancreatic Cancer Drug Data Request (RGEN)

4-26-12-Shares of Repligen (NASDAQ:RGEN) are trading over 45% lower after trading resumed in the shares that were halted on news that biotechnology firm would be asked for more information on its pancreatic imaging treatment by the FDA.The FDA, which was due to decide whether to approve the drug by June 21st, canceled a May meeting of advisers to review the compound, RG1068, the company said in a statement today.The Massachusetts-based firm expects regulators will request additional data on the drug.SmarTrend is bullish on shares of Repligen and our subscribers were alerted to buy on January 25, 2012 at $3.69. The stock has risen 14.7% since the alert was issued.

Analyst Moves: MDRX, OXY

Allscripts (MDRX) was downgraded today from buy to hold by Jefferies (JEF) with a price target of $10.50 due weak bookings and poor operating results. Shares are lower by about 35.5 percent.

Friday 4/27 Insider Buying Report: FSL, S

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

Amylin Pharmaceuticals Reports Narrower-Than-Expected Loss (AMLN)

4-26-12-Amylin Pharmaceuticals (NASDAQ:AMLN) reported a Q1 loss of $0.23, topping estimates by $0.04.Revenues in the quarter were flat at $153.7 million, missing estimates by $8 million.Amylin Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for diabetes and obesity. The Company’s marketed products include treatments for adults with type 1 and type 2 diabetes.

UPS Announces Earnings

United Parcel Service (UPS) announced that first quarter net income increased by ten percent due to growth in the US domestic and supply chain divisions, as well as in its freight unit. Net income was $970 million, or $1 per share, up from $915 million, or 91 cents per share in the same period last year.

Vulcan Materials Shares Teeter On Mixed Results (VMC)

4-26-12-Shares of Vulcan Materials (NYSE:VMC) are trading only slightly lower after it reported mixed results this morning.Vulcan reported a Q1 loss of $0.42 per share, beating estimates by a penny.Revenues in the quarter rose 10% year-over-year to $500 million, missing estimates by $17 million.SmarTrend currently has Vulcan Materials in a Downtrend. Since 2008, SmarTrend subscribers trading Vulcan Materials using our alerts outperformed the stock by 219%. We are monitoring these developments and will alert subscribers to any change in trend.

Caterpillar Beats EPS Estimates And Raises Annual EPS Guidance

Caterpillar (NYSE:CAT) reported Q1 EPS of $2.37, vs. estimates of $2.13.Revenues in the quarter rose 23% year-over-year to $15.98 billion, missing estimates by $240 million.Caterpillar says it sees annual EPS of about $9.50 per share, vs. its prior guidance of $9.25 per share. The company kept its sales guidance unchanged.